Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellsorba.

Hiroshi Shibata1, Toshiji Kuriyama, Naokuni Yamawaki

  • 1Development and Scientific Affairs Department, Asahi Medical Co., Tokyo, Japan. shibata.hd@om.asahi-kasei.co.jp

Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
|August 19, 2003
PubMed
Summary

Cellsorba is a leukocyte removal filter that treats inflammatory diseases by adsorbing white blood cells. Leukocytapheresis (LCAP) therapy using Cellsorba shows therapeutic effects for conditions like ulcerative colitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiration-action coupling during self-initiated action: Evidence for action alignment with ongoing breathing.

Biological psychology·2026
Same author

Orthography implicitly influences the trustworthiness of onscreen information in the Japanese language.

Acta psychologica·2026
Same author

Respiratory and Cardiac Phase Coupling With Voluntary Actions Across Motor Tasks.

Psychophysiology·2026
Same author

Enhanced insecticidal activity of isoparaffin by ozone as an adjuvant.

Scientific reports·2025
Same author

Early Detection of Age-Related Decline of Muscle Cell Mass by Intracellular Water Assessment Compared With MRI or DXA.

Journal of cachexia, sarcopenia and muscle·2025
Same author

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.

Scientific reports·2025

Area of Science:

  • Biomedical engineering
  • Immunology
  • Medical technology

Background:

  • Leukocyte removal filters are crucial for managing inflammatory and autoimmune diseases.
  • Cellsorba, a leukocyte removal filter by Asahi Medical Co., utilizes extracorporeal circulation to adsorb white blood cells.
  • Leukocytapheresis (LCAP) therapy has demonstrated efficacy in various autoimmune and inflammatory conditions.

Purpose of the Study:

  • To review the application and therapeutic outcomes of Cellsorba.
  • To highlight the role of Cellsorba in treating inflammatory diseases, particularly ulcerative colitis (UC).
  • To discuss the contribution of Cellsorba to improving patients' quality of life.

Main Methods:

  • Utilizing the Cellsorba column for leukocytapheresis (LCAP).

Related Experiment Videos

  • Perfusion of peripheral blood through simple extracorporeal circulation.
  • Reviewing existing reports on therapeutic results for various diseases.

    • Main Results:

    • LCAP therapy with Cellsorba has shown therapeutic effects in inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, and neurologic diseases.
    • Cellsorba is approved and covered by Japanese national health insurance for active ulcerative colitis (UC).
    • The therapy contributes to enhancing the quality of life for many UC patients.

    Conclusions:

    • Cellsorba is an effective leukocyte removal filter for treating a range of inflammatory and autoimmune diseases.
    • Its use in LCAP therapy, especially for ulcerative colitis, offers significant clinical benefits.
    • Cellsorba represents a valuable therapeutic option, improving patient quality of life.